1 |
Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol 2010; 47: 325-9.
DOI
|
2 |
Jung HS, Kang JK, Yoo SH. Epidemiological study on the incidence of herpes zoster in the nearby Cheonan. Korean J Pain 2015; 28: 193-7.
DOI
|
3 |
Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132 Suppl 1: S52-9.
DOI
|
4 |
Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-51.
DOI
|
5 |
Zaal MJ, Volker-Dieben HJ, D'Amaro J. Risk and prognostic factors of postherpetic neuralgia and focal sensory denervation: a prospective evaluation in acute herpes zoster ophthalmicus. Clin J Pain 2000; 16: 345-51.
DOI
|
6 |
Pica F, Gatti A, Divizia M, Lazzari M, Ciotti M, Sabato AF, et al. One-year follow-up of patients with long-lasting postherpetic neuralgia. BMC Infect Dis 2014; 14: 556.
DOI
|
7 |
Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect 2015; 70: 178-86.
DOI
|
8 |
Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1-26.
DOI
|
9 |
Jeon Y. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 2015; 28: 177-84.
DOI
|
10 |
Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7.
DOI
|
11 |
Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157: 909-12.
DOI
|
12 |
Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med 2004; 29: 454-61.
|
13 |
Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54: 922-8.
DOI
|
14 |
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
DOI
|
15 |
Kim KH. Herpes zoster vaccination. Korean J Pain 2013; 26: 242-8.
DOI
|
16 |
Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1,414 patients. Korean J Pain 2013; 26: 21-6.
DOI
|